MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: The Importance of RET-He in the Diagnosis of Iron Deficiency and Iron Deficiency Anemia and the Evaluation of Response to Oral Iron Therapy.
Author: Uçar MA, Falay M, Dağdas S, Ceran F, Urlu SM, Özet G.
Journal: J Med Biochem; 2019 Oct; 38(4):496-502. PubMed ID: 31496915.
Abstract:
BACKGROUND: The purpose of this study is to investigate whether or not reticulocyte hemoglobin equivalent (RET-He) is a superior indicator of blood count and other iron parameters in terms of diagnosing iron deficiency (ID) and iron deficiency anemia (IDA), and thus evaluating a patient's response to oral iron treatment. METHODS: The research population consisted of 217 participants in total: 54 control, 53 ID, 58 non-ID anemia, and 52 IDA patients. A hemoglobin (Hb) value of < 130.0 g/L was defined as indicating anemia for men, while an Hb value of < 120.0 g/L was defined as indicating anemia for women. All patients were administered 270 mg oral elemental iron sulphate daily. RESULTS: The RET-He was significantly lower in the IDA group, compared to other groups (IDA: 21.0 ± 4.1, ID: 26.0 ± 4.9, non-ID anemia: 32.1 ± 6.8, control: 36.6 ± 7.0; < 0.001). The ID group had a lower RET-He compared to the non-ID anemia group and the control group. On the 5th day of treatment, the ID and IDA group showed no significant differences in terms of Hb while the RET-He level demonstrated a significant increase. The increase in the RET-He level observed in the IDA group on the 5th day was significantly higher compared to the increase observed in the ID group. A RET-He value of 25.4 pg and below predicted ID diagnosis with 90.4% sensitivity and 49.1% specificity in IDA patients, compared to the ID group. CONCLUSIONS: The results of our study, therefore, suggest that RET-He may be a clinically useful marker in the diagnosis of ID and IDA. UVOD: Svrha ove studije je utvrđivanje da li je retikulocitni ekvivalent hemoglobina (RET-He) superiorni indikator krvne slike i drugih parametara gvožđa u smislu dijagnostikovanja deficita gvožđa (ID) i anemije usled nedostatka gvožđa (IDA), kako bi se na taj način procenila reakcija pacijenata na peroralni tretman gvožđem. METODE: Populacija na kojoj je vršeno ispitivanje se sastojala od ukupno 217 učesnika: 54 kontrolna učesnika, 53 sa ID, 58 anemičnih (ali ne u vezi sa ID) i 52 IDA pa-cijenta. Vrednost hemoglobina Hb < 130,0 g/L je definisana kao indikacija anemije kod muškaraca, dok je vrednost Hb < 120,0 g/L definisana kao indikacija anemije kod žena. Svim pacijentima je dnevno oralno davano 270 mg elementarnog gvožđa sulfata. REZULTATI: U poređenju sa drugim grupama RET-He je bio značajno niži u IDA grupi (IDA: 21,0 ± 4,1; ID: 26,0 ± 4,9; ne-ID anemična grupa: 32,1 ± 6,8; kontrola: 36,6 ± 7,0; < 0,001). ID grupa je imala niži RET-He u poređenju sa ne-ID grupom anemije i kontrolnom grupom. Petog dana tretmana ID i IDA grupa nisu pokazale značajne razlike u smislu Hb dok je RET-He nivo pokazao značajno povećanje. Porast RET-He nivoa koji je uočen u IDA grupi petog dana bio je značajno veći u poređenju sa porastom koji je primećen u ID grupi. Vrednost RET-He od 25,4 pg i manje je predvidela ID dijagnozu sa 90,4% osetljivosti i 49,1% specifićnosti kod IDA pacijenata, u poređenju sa ID grupom. ZAKLJUČAK: Rezultati našeg istraživanja sugerišu da RET-He može biti klinički koristan marker u dijagnostici ID i IDA.

[Abstract] [Full Text] [Related] [New Search]